News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
Market overviews
Direct comparison of products for laboratory and process: Use the comprehensive market overviews to compare products according to your requirements and obtain further information from suppliers.
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
07-Feb-2006 - BTG plc and Senexis Limited announced that BTG has exclusively licensed its novel inhibitors of amyloid-induced toxicity and neuroinflammation to Senexis. These compounds may be useful in the treatment of Alzheimer's Disease and other amyloid-based diseases. BTG will receive milestones payments ...
03-Feb-2006 - Symphogen A/S and Biovitrum AB have entered into a co-development and commercialization agreement for Sym001, Symphogen's lead product. Sym001 is a combination of 25 different recombinant anti-Rhesus D antibodies for the treatment of both Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic ...
02-Feb-2006 - CombinatoRx, Incorporated and Fovea Pharmaceuticals SA announced a collaboration for the potential development and commercialization of combination drugs to treat ophthalmic diseases. The agreement unites CombinatoRx's leadership in the systematic discovery of novel combination drug candidates ...
Negotiations for the exclusive right to manufacture the drug for a new proprietary use
02-Feb-2006 - Microbix Biosystems Inc. announced that it has taken over the production of its urokinase product from Genpharm Inc. and will directly operate the manufacturing facilities. The two companies, which have been working together over the past three years to commercialize the product, have now amended ...
01-Feb-2006 - Cangene announced that the U.S. Food and Drug Administration (FDA) has approved Cangene's HepaGam B(TM) for treatment following acute exposure to hepatitis B virus. HepaGam B(TM) is Cangene's hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the ...
31-Jan-2006 - Geron Corporation announced the presentation of a new production protocol to differentiate islet cells from human embryonic stem cells (hESCs) for the treatment of diabetes. Dr. Anish Majumdar, Geron's Senior Director of Cell Therapy Research, presented an improved method of deriving islet cells ...
31-Jan-2006 - Pharmexa-Epimmune Inc., a US subsidiary of Pharmexa A/S, and the HIV Vaccine Trials Network (HVTN) announcesd the opening of a phase I study designed to test the safety of two HIV vaccine candidates developed by Pharmexa-Epimmune. This trial will test whether the two study vaccines, which are ...
31-Jan-2006 - Patheon Inc. announced that Patheon has entered into a five-year master supply agreement with Merck & Co., Inc. to provide commercial manufacturing and pharmaceutical development services to Merck, and that Merck has selected Patheon as one of Merck's strategic partners for commercial ...
31-Jan-2006 - Transgene S.A. announced that it has been awarded funding by the Lyon Biopole Competitiveness Cluster (Pole de competitivite) for the development of its therapeutic vaccine candidate against hepatitis C chronic infection (HCV). This funding is expected to total EUR 1.3 million over the next three ...
Proposed Indication Includes All Patients with Pompe Disease
31-Jan-2006 - Genzyme Corp. announced that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency has adopted a positive opinion on the marketing authorization application for Myozyme® (alglucosidase alfa). The CHMP unanimously recommended full approval of Myozyme for the treatment ...
© 1997-2024 LUMITOS AG, All rights reserved